CADTH Reimbursement Reviews and Recommendations
A comprehensive assessment of the clinical effectiveness, cost effectiveness, and patient perspectives of a drug or drug class. The assessment informs non-binding recommendations that help guide Canada's federal, provincial, and territorial governments’ (except Quebec) reimbursement decisions for drug plans. Implementation advice and funding algorithms are provided where applicable.
Reimbursement Reviews and Recommendations, formerly known as Common Drug Reviews, are published in CADTH’s Canadian Journal of Health Technologies, an open-access, scientific and policy journal. Topics covered are relevant to health policy decision-makers, clinicians, patients, caregivers, the pharmaceutical and medical device industry, and the Canadian and global health technology assessment community.
CADTH Common Drug Reviews was renamed to CADTH Reimbursement Reviews and Recommendations on Oct. 29, 2021.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/